Assessment of methylated BCAT1 and IKZF1 circulating tumor DNA as a potential diagnostic and prognostic biomarker in esophagogastic cancers

Research output: Contribution to journalMeeting Abstractpeer-review

Abstract

Esophagogastric cancers (EG cancers) are associated with high mortality and poor treatment outcomes due to advanced disease at diagnosis. Reliable non-invasive biomarkers are lacking for detection and prognostication. The aim of this study was to assess the clinical utility of methylated BCAT1 and IKZF1 circulating tumour DNA (ctDNA) for detection and prognosis of EG cancers.
Original languageEnglish
Pages (from-to)348
Number of pages2
JournalJournal of Clinical Oncology
Volume40
Issue number4 suppl
DOIs
Publication statusPublished - 1 Feb 2022
Event2022 ASCO Gastrointestinal Cancers Symposium - San Francisco, United States
Duration: 20 Jan 202222 Jan 2022

Keywords

  • BCAT1
  • IKZF1
  • esophagogastric cancers
  • Diagnostic biomarkers
  • Prognostic biomarkers
  • tumor DNA

Fingerprint

Dive into the research topics of 'Assessment of methylated BCAT1 and IKZF1 circulating tumor DNA as a potential diagnostic and prognostic biomarker in esophagogastic cancers'. Together they form a unique fingerprint.

Cite this